Skip to main content

Table 2 Risk ratios of ACR20/50 response rates of tofacitinib vs.40 mg adalimumab at month 3[21] and 6[22]

From: Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis

 

ACR20

ACR50

Dose of tofacitinib

Sample size (tofacitinib, adalimumab)

Risk ratio [95% CI]

Sample size (tofacitinib, adalimumab)

Risk ratio [95% CI]

Month 3

    

1 mg bid

54, 53

0.88 [0.52, 1.50]

54, 53

0.59 [0.23, 1.51]

3 mg bid

51, 53

1.09 [0.67, 1.80]

51, 53

1.25 [0.59, 2.63]

5 mg bid

49, 53

1.65 [1.08, 2.53]

49, 53

1.95 [1.00, 3.80]

10 mg bid

61, 53

1.97 [1.32, 2.92]

61, 53

2.35 [1.26, 4.38]

15 mg bid

57, 53

2.01 [1.35, 2.98]

57, 53

2.70 [1.46, 4.98]

Month 6,

    

5 mg bid

196, 199

1.09 [0.89, 1.33]

N/A

N/A

10 mg bid

196: 199

1.11 [0.91, 1.36]

N/A

N/A

  1. bid twice daily; CI confidence interval; N/A, not applicable.